Frequencies of immunological aberrations in acute schizophrenia;Zur haufigkeit immunologischer auffalligkeiten bei akuten schizophrenien

Fortschritte der Neurologie Psychiatrie

Volumn 67, Issue 5, 1999, Pages 218-224

  Fabisch, Hans ^a,b   Fabisch, K ^a   Langs, G ^a   Demel, U ^c   Wieselmann, G ^a   Tilz, G P ^c   Zapotoczky, H G ^a  

^a Psychiat Neurol Univ Klin   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ADULT; ARTICLE; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; DISORIENTATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; SCHIZOPHRENIA; SEROLOGY; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOPATHOLOGY; PSYCHOLOGY;

ACUTE DISEASE; ADULT; HUMANS; IMMUNE SYSTEM DISEASES; MALE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0033018486     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993998     Document Type: Article

References (48)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. DSM-IV. Washington, DC: APA 1994
2. Andreasen, N. C., S. Olsen: Negative vs. Positive Schizophrenia. Arch. Gen. Psychiatry 39 (1982) 789-794
3. Andreasen, N. C.: Negative symptoms in schizophrenia: Definition and reliability. Arch. Gen. Psychiatry 39 (1982) 784-788
4. Berrios, G. E.: Positive and negative symptoms and Jackson: A conceptual history. Arch. Gen. Psychiatry 42 (1985) 95-97
5. Bessler, H., Z. Leventhal, L. Karp, I. Modai, M. Djaldetti, A. Weizman: Cytokine production in drug-free and neuroleptic treated schizophrenic patients. Biol. Psychiatry 38 (1995) 297-302
6. Bleuler, E. u. M. Bleuler: Lehrbuch der Psychiatrie. 15. Neubearb. Aufl. v. M. Bleuler. Springer, Berlin 1983
7. Costello, Ch. G.: From Symptoms of Schizophrenia to Syndromes of Schizophrenia. In: Costello, Ch. G. (ed.): Symptoms of Schizophrenia. Wiley & Sons, New York (1993) 291-303
8. Dameschek, W.: The white blood cells in dementia praecox and dementia paralytica. Arch. Neurol. Psychiatry 24 (1930) 855
9. DeLisi, L. E.: Neuroimmunology: clinical studies of schizophrenia and other psychiatric disorders. In: Nasrallah, H. A. and D. K. Weinberger (ed.): Handbook of Schizophrenia, Vol. 1. The Neurology of Schizophrenia. Elsevier, Amsterdam (1986) 377-396
10. DeLisi, L. E.: Viral and Immune Hypotheses for Schizophrenia. In: Meltzer, H. (ed.): Psychopharmacology. The Third Generation of Progress. Raven Press, New York (1987) 765-771
11. DeLisi, L. E., R. J. Wyatt: Abnormal immune regulation in schizophrenic patients. Psychopharmacol. Bull. 18 (1982) 158-163
12. Ehrnst, A., F. A. Wiesel, L. Bjerkenstedt, B. Tribukait, J. Jonsson: Failure to detect immunologic stigmata in schizophrenia. Neuropsychobiology 8 (1982) 169-171
13. Ganguli, R., B. Rabin: Increased serum interleukin 2 receptor concentration in schizophrenia and brain damaged subjects. Arch. Gen. Psychiatry 46 (1989) 292
14. Ganguli, R., Z. Yang, G. Shurin, K. N. Chengappa, J. S. Brar, A. V. Gubbi: Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51 (1994) 1-10
15. Glaser, R., J. Rice, C. E. Speicher, J. C. Stout, J. K. Kiecolt-Glaser: Stress depress Interferon production by leucocytes concomitant with a decrease in natural killer cell activity. Behav. Neurosci. 100 (1986) 675-678
16. Hornberg, M., V. Arolt, I. Wilke, A. Kruse, H. Kirchner: Productions of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schiz. Res. 15 (1995) 237-242
17. Huber, G.: Psychiatrie. 5. Auflage. Schattauer, Stuttgart (1994)
18. Katila, H., B. Appelberg, M. Hurme, R. Rimon: Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 12 (1994) 29-34
19. Kay, S. R., A. Fiszbein, L. A. Opler: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
20. Kay, S. R.: Positive and Negative Syndromes in Schizophrenia. Assessment and Research. Brunner/Mazel, New York (1991)
21. Kendler, K. S., A. M. Gruenberg, M. T. Tsuang: Subtype stability in schizophrenia. Am. J. Psychiatry 142 (1985) 827-832
22. Klosterkötter, J.: Das Vulnerabilitätskonzept bei schizophrenen Erkrankungen. In: Möller, H. J., A. Deister (Hrsg.): Vulnerabilität für affektive und schizophrene Erkrankungen. Springer, Wien (1996) 11-21
23. Klosterkötter, J.: Zur definitorischen Neufassung der schizophrenen Störungen in ICD-10 und DSM-IV. Fortschr. Neurol. Psychiat. 66 (1998) 133-143
24. Maes, M., H. Y. Meltzer, E. Bosmans: Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89 (1994) 346-351
25. Maes, M., E. Bosmans, J. Calabrese, R. Smith, H. Y. Meltzer: Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. Psychiatry Res. 29 (1995 a) 141-152
26. Maes, M., H. Y. Meltzer, P. Buckley, E. Bosmans: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur. Arch. Psychiatry Clin. Neurosci. 244 (1995b) 325-329
27. Maes, M., E. Bosmans, R. Ranjan, B. Vandoolaeghe, H. Y. Meltzer, M. De Ley, R. Berghmans, G. Stans, R. Desnyder: Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 21 (1996) 39-50
28. McAllister, C. G., D. P. van Kammen, T. J. Rehn, A. L. Miller, J. Gurklis, M. E. Kelley, J. Yao, J. L. Peters: Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry 152 (1995) 1291-1297
29. Müller, N., E. Hofschuster, M. Ackenheil, R. Eckstein: T-Cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr. Scand. 87 (1993) 66-71
30. Müller, N., M. Empl, M. Riedel, M. Schwarz, M. Ackenheil: Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 247 (1997a) 308-313
31. Müller, N., M. Empl, A. Putz, M. Schwarz, M. Ackenheil: Immunological Effects of Treatment in Schizophrenia. In: Henneberg, A. E., W. P. Kaschka: Immunological Alterations in Psychiatric Diseases. Karger, Basel (1997b) 78-84
32. Nitsch, J. R.: Aspekte der Streßforschung. In: Nitsch, J. R. (Hrsg.): Streß, Theorien, Untersuchungen, Maßnahmen. Huber, Bern (1981) 27-160
33. Noy, S., A. Achiron, N. Loar: Schizophrenia and autoimmunity - a possible etiological mechanism? Neuropsychobiology 30 (1994) 157-159
34. Nuechterlein, K. H., M. E. Dawson: A Heuristic Vulnerability/ Stress Model of Schizophrenic Episodes. Schizophr. Bull. 10 (1984) 300-312
35. Pollmächer, Th., D. Hinze-Selch, J. Mullington, F. Holsboer: Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors. Arch. Gen. Psychiatry 52 (1995) 877-878
36. Pollmächer, Th., D. Hinze-Selch, Th. Fenzel, Th. Kraus, A. Schuld, J. Mullington: Plasma Levels of Cytokines and Soluble Cytokine Receptors During Treatment With Haloperidol. Am. J. Psychiatry 154 (1997) 1763-1765
37. Rapaport, M. H., C. G. McAllister, D. Pickar, D. L. Nelson, S. M. Paul: Elevated levels of soluble interleukin 2 receptors in schizophrenia. Arch. Gen. Psychiatry 46 (1989) 291-292
38. Rapaport, M. H., J. B. Lohr: Serum soluble interleukin 2-receptors in neuroleptic naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 90 (1994) 311-315
39. Reichelt, K. L., J. Landmark: Specific IgA antibody increases in schizophrenia. Biol. Psychiatry 37 (1995) 410-413
40. Resch, F., H. Aschauer, A. Urch, G. Schönbeck, G. Aschauer-Treiber, Ch. Müller et al.: Funktion lytischer Effektorzellen bei schizophrenen Patienten. Wien. Klin. Wochenschr. 100 (1988) 404-407
41. Resch, F., H. N. Aschauer, G. Aschauer-Treiber, A. Oppolzer: Psychoimmunologie bei Psychosen aus dem schizophrenen Formenkreis. In: Kaschka, W. P., H. Aschauer (Hrsg.): Psychoimmunologie. Thieme, Stuttgart (1990) 105-115
42. Sasaki, T., S. Nanko, R. Fukuda, T. Kawate, H. Kunugi, H. Kazamatsuri: Changes of iminunological function after acute exazerbation in schizophrenia. Biol. Psychiatry 35 (1994) 173-178
43. Schindler, L., M. Leroux, J. Beck, H. W. Moises, H. Kirchner: Studies of cellular immunity, serum interferon titers, and natural killer cell activity in schizophrenic patients. Acta Psychiatr. Scand. 73 (1986) 651-657
44. Sirota, P., K. Schild, A. Elizur, M. Djaldetti, P. Fishman: Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995) 75-83
45. Tilz, G. P.: Klinische Immunbiologie und Immunhämatologie. In: Begemann, H., J. Rastetter (Hrsg.): Hämatologie. Thieme, Stuttgart (1993) 118-163
46. Weitbrecht, H. J., J. Glatzel: Psychiatrie im Grundriß. Springer, Berlin (1979)
47. Zarrabi, M. H., F. Zucker, R. M. Miller, G. S. Derman, J. A. Romano, A. O. Hartnett: Immunologic and coagulation disorders in chlorpromazine treated patients. Ann. Int. Med. 91 (1979) 194-199
48. Zubin, J., B. Spring: Vulnerability - a new view of schizophrenia. J. Abnorm. Psychology 86 (1977) 103-126